Federal Regulators Move to Halt Major Veterinary Supply Merger
Washington, Monday, 16 November 2026.
Federal regulators and 13 states sued to stop Covetrus’s $3.5 billion acquisition of rival MWI, warning that unifying the top two distributors could inflate nationwide pet care costs.
Antitrust Challenge Launched Against $3.5 Billion Deal
On Friday, 14 November 2026, the Federal Trade Commission (FTC) filed a lawsuit in the U.S. District Court for the Southern District of New York to permanently enjoin Covetrus’s $3.5 billion acquisition of MWI Animal Health, the veterinary distribution arm of Cencora, Inc. (NYSE: COR) [1][2][3]. Thirteen state attorneys general joined the FTC in the action, arguing that merging the two largest veterinary suppliers would substantially lessen competition and drive up procurement costs for clinics and pet owners nationwide [2][5][6]. The antitrust challenge reflects heightened federal scrutiny of healthcare and pharmaceutical supply-chain consolidations, leaving Cencora’s planned divestiture and capital-allocation strategy in legal and financial limbo [1][3].
Market Position and Competitive Dynamics
Covetrus and MWI currently operate as the two dominant national distributors of pharmaceuticals, vaccines, surgical supplies, and large-animal equipment to independent and corporate veterinary practices in the United States [2][4]. Regulators allege that the proposed merger would create a combined entity controlling more than 50% of the veterinary distribution market, with no meaningful constraints from fringe competitors or new entrants [5][6]. The FTC’s complaint highlights a years-long price war—fueled by online marketplaces such as Vetcove and distributor programs like Covetrus’s VetSuite—that has kept prices low for veterinarians and pet owners [2][4][6]. According to Covetrus, more than 60% of U.S. veterinary practices now use online purchasing platforms that aggregate dozens of distributors and thousands of manufacturers, creating downward pressure on prices across the supply chain [4][7].
Regulatory Rationale and Economic Impact
FTC Director of the Bureau of Competition Daniel Guarnera stated that eliminating head-to-head rivalry between Covetrus and MWI would reduce competition in an already concentrated market, ultimately increasing costs for veterinarians and their customers [2][3][6]. The Commission voted 2-0 to authorize the lawsuit, arguing that the merger violates Section 7 of the Clayton Act and Section 5 of the FTC Act by creating highly concentrated markets for both veterinary clinic distribution and large corporate-account distribution [2][5][6]. Nebraska Attorney General Suzanne Gage emphasized that the loss of competition could lead to higher prices, diminished service, and reduced product choice for clinics and, ultimately, pet owners [6].
Corporate and Market Reactions
Cencora’s shares rose approximately 2% during the market session on Friday following the FTC announcement, reflecting investor uncertainty about the deal’s completion timeline [1]. Covetrus, majority-owned by private-equity firms Clayton, Dubilier & Rice LLC and TPG Inc., stated it is fully prepared to defend the transaction in court and remains confident in the merger’s merits and its potential to make animal healthcare more affordable and accessible [4][7][8]. The company highlighted the role of national shipping carriers—UPS, USPS, and FedEx—in enabling low-cost, nationwide delivery of veterinary products, which has historically constrained distributor pricing power [7].
Court Proceedings and Next Steps
The complaint was filed on 13 November 2026, and Covetrus indicated it will vigorously contest the FTC’s allegations in federal court [2][3][8]. The states of Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon, and Texas joined the FTC as plaintiffs, underscoring the bipartisan nature of the antitrust challenge [5][6]. While the FTC has not publicly indicated a deadline for resolution, legal observers note that antitrust injunction proceedings typically proceed on an expedited schedule once a complaint is filed [9].
Sources
- ca.marketscreener.com
- www.ftc.gov
- www.dvm360.com
- www.prnewswire.com
- www.semafor.com
- ago.nebraska.gov
- www.dvm360.com
- www.prnewswire.com
- ca.marketscreener.com